🧪
Cell Line Development (CLD)
Proprietary platform to derive high-producing CHO host cell lines and stable clones tailored to your molecule.
Learn More →CHO Medium
Your vision is our mission — advanced cell lines & biologics
We design high-performance CHO host cell lines, matched media & feeds and scalable upstream/downstream processes — fast, reliable, and GMP-ready.
Trusted by innovators
GMP Compliant
Platform
CHO Suite
R2U Cells • Media & Feed
Learn →
Our Development Services
⚗️
Upstream Processing (USP)
Bioreactor process design and scale-up guidance that preserves product quality and increases titer.
Learn More →🧾
Downstream Processing (DSP)
Integrated purification workflows with in-line analytics and robust CQA control.
Learn More →📈
Analytical Development
Custom analytical methods for potency, purity and stability to support regulatory filings.
Learn More →Key Products
CHO Medium & Feeds
Proprietary formulations engineered to maximize productivity while preserving product quality. Optimized for CHO cell cultures with enhanced nutrient delivery and reduced metabolic waste.
Explore FormulationsReady-to-use Cell Lines (R2U-Cells)
Adapted CHO host lines optimized for biosimilar manufacturing and rapid tech transfer. Pre-validated for high productivity and stability in various production systems.
View Cell LinesNews Update
Fonix Pharma at CPHI Milan 2024
Visit us at booth 20C11 to discover our latest platform improvements and meet our scientific team.
GMP Certified
Achievement of GMP compliance — reinforcing our processes and quality management across operations.
Advancing Rare Disease Solutions
Fonix Pharma contributes to research programs and partnerships focused on rare disease therapies.
About Fonix Pharma
Fonix Pharma was established in 2025 in a key biotech location. We specialize in the development of monoclonal cell lines for the production of advanced biologics and biosimilars.
Using our platform, we deliver robust processes — from cell line development to GMP-ready manufacturing support — with an emphasis on speed and cost-effectiveness.
Read More
Innovation in Biologics